Hansa Biopharma appoints Maria Törnsén as chief operating officer and US president
Ella Day | May 14, 2025 | Appointment | Research and Development | Corporate, Hansa Biopharma, Immunology, Pharmacy, biopharma, chief operating officer (COO), immunology
Swedish biopharma company Hansa Biopharma has appointed Maria Törnsén as chief operating officer (COO) and president US effective 19 May 2025. Törnsén will report to CEO Renée Aguiar-Lucander and join the company’s executive committee.
Törnsén brings more than 20 years of experience in global and US biopharma markets. She most recently served as president of North America at Calliditas Therapeutics, leading its US commercial and medical affairs operations until its acquisition by Asahi Kasei Corporation in 2024. Her other leadership roles include senior vice president and US general manager at Sarepta Therapeutics, and vice president and global therapeutic area head at Sanofi Genzyme.
“We are pleased to welcome Maria to Hansa’s leadership team,” said Aguiar-Lucander. “Her deep expertise in rare diseases and gene therapy, combined with a strong record of commercial execution, will be pivotal as we advance into our next phase.”
“I’m excited to join Hansa at such a dynamic time,” said Törnsén. “I look forward to building on the momentum of IDEFIRIX and supporting upcoming milestones in the second half of 2025.”
Hansa Biopharma develops innovative treatments for rare immunological conditions. Its lead product, IDEFIRIX, is approved in Europe for enabling kidney transplantation in highly sensitised patients.
Ella Day
14/5/25
Related Content
Chronic spontaneous urticaria – the impact on patient quality of life, ongoing developments in treatments and the importance of greater awareness
The current forms of immunotherapy, how T cell therapy works and what the future holds
Symeres announces acquisition of DGr Pharma
Symeres, a Contract Research, Development and Manufacturing Organization (CRDMO) has acquired DGr Pharma, a drug …
Hansa Biopharma announces positive data for Duchenne muscular dystrophy gene therapy
Hansa Biopharma has announced encouraging results from its ongoing SRP-9001-104 trial, which is investigating the …
